Last reviewed · How we verify
ocrelizumabu 200mg
ocrelizumabu 200mg is a B-cell depleting monoclonal antibody; immunosuppressant Small molecule drug developed by Chugai Pharmaceutical. It is currently in discontinued development.
Ocrelizumab selectively depletes CD20+ B lymphocytes to suppress autoimmune-mediated inflammation.
Ocrelizumab 200 mg is a monoclonal antibody developed by Chugai Pharmaceutical that targets CD20-expressing B cells, designed for the treatment of rheumatoid arthritis and other autoimmune conditions. The drug mechanism involves selective depletion of B lymphocytes, which play a central role in the pathogenesis of autoimmune diseases by producing autoantibodies and pro-inflammatory cytokines. Ocrelizumab entered clinical development with a Phase 2 trial in rheumatoid arthritis (N=152) sponsored by Chugai Pharmaceutical; however, this trial was terminated, and the program was subsequently discontinued. The discontinuation suggests either insufficient efficacy signals, safety concerns, or strategic portfolio decisions by Chugai, as the competitive landscape for B-cell-targeting biologics in RA was already well-established with approved agents such as rituximab and ocrelizumab (Ocrevus, developed by Roche/Genentech for MS). No FDA approval, EMA marketing authorization, or regulatory designation was achieved. The commercial and clinical significance of this asset is minimal given its discontinued status and lack of regulatory advancement beyond early-stage clinical evaluation.
At a glance
| Generic name | ocrelizumabu 200mg |
|---|---|
| Sponsor | Chugai Pharmaceutical |
| Drug class | B-cell depleting monoclonal antibody; immunosuppressant |
| Target | CD20 (cluster of differentiation 20) |
| Modality | Small molecule |
| Therapeutic area | Immunology |
| Phase | discontinued |
Mechanism of action
Ocrelizumab is a monoclonal antibody that binds to CD20, a cell surface antigen expressed on B lymphocytes at various stages of maturation. By targeting CD20, the drug triggers B-cell destruction through multiple mechanisms including antibody-dependent cellular cytotoxicity (ADCC), complement-dependent cytotoxicity (CDC), and direct induction of apoptosis. In autoimmune diseases like rheumatoid arthritis, B cells contribute to disease pathology by producing autoantibodies (such as rheumatoid factor and anti-CCP antibodies), presenting antigens to T cells, and secreting pro-inflammatory cytokines including TNF-α, IL-6, and IL-10. By depleting these B-cell populations, ocrelizumab aims to interrupt the autoimmune cascade and reduce joint inflammation, synovitis, and progression of structural damage. The selective targeting of CD20 allows for B-cell depletion while largely sparing other immune cell populations, though some immunosuppression is expected.
Approved indications
Pipeline indications
- Rheumatoid Arthritis — Phase 2
Common side effects
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ocrelizumabu 200mg CI brief — competitive landscape report
- ocrelizumabu 200mg updates RSS · CI watch RSS
- Chugai Pharmaceutical portfolio CI
Frequently asked questions about ocrelizumabu 200mg
What is ocrelizumabu 200mg?
How does ocrelizumabu 200mg work?
Who makes ocrelizumabu 200mg?
What drug class is ocrelizumabu 200mg in?
What development phase is ocrelizumabu 200mg in?
What does ocrelizumabu 200mg target?
Related
- Drug class: All B-cell depleting monoclonal antibody; immunosuppressant drugs
- Target: All drugs targeting CD20 (cluster of differentiation 20)
- Manufacturer: Chugai Pharmaceutical — full pipeline
- Therapeutic area: All drugs in Immunology
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing